<DOC>
	<DOCNO>NCT02831218</DOCNO>
	<brief_summary>The purpose study compare clinical outcome QCA ( quantitative coronary angiography ) -guided imaging-guided strategy patient native coronary artery disease undergo Bioresorbable Vascular Scaffold implantation .</brief_summary>
	<brief_title>Quantitative Coronary Angiography Versus Imaging GUIDancE Bioresorbable Vascular Scaffold Implantation</brief_title>
	<detailed_description />
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<criteria>Men woman least 18 year age Typical chest pain objective evidence myocardial ischemia suitable elective percutaneous coronary intervention Native coronary artery lesion lesion length ≤ 50mm reference vessel diameter 2.3 3.75mm QCA ( quantitative coronary angiography ) assessment The patient guardian agree study protocol schedule clinical followup , provide informed , write consent , approve appropriate Institutional Review Board/Ethical Committee respective clinical site . Angiographic exclusion criterion : following 1 . Small vessel : mean reference size &lt; 2.3 mm QCA ( quantitative coronary angiography ) 2 . True bifurcation lesion large side branch ( reference vessel diameter &gt; 2.3mm ) require complex twostent approach 3 . Left main lesion 4 . Ostial lesion within 3mm origin : right coronary artery , leave anterior descend artery , leave circumflex artery 5 . Impaired delivery Absorb BVS expect : Extreme angulation ( ≥90° ) proximal within target lesion . Excessive tortuosity ( ≥two 45° angle ) proximal within target lesion . Moderate heavy calcification proximal within target lesion . 6 . Instent restenotic lesion STelevation myocardial infarction undergo primary percutaneous coronary intervention ( 12 24 hour symptom onset ) Prior percutaneous coronary intervention within target vessel last 12 month . Prior percutaneous coronary intervention within nontarget vessel peripheral intervention acceptable perform anytime &gt; 30 day index procedure , 24 hour 30 day index procedure successful uncomplicated . Left ventricular ejection fraction ( LVEF ) &lt; 30 % Hypersensitivity contraindication device material degradants ( everolimus , poly ( Llactide ) , poly ( DLlactide ) , lactide , lactic acid ) cobalt , chromium , nickel , platinum , tungsten , acrylic fluoro polymer adequately premedicated . Persistent thrombocytopenia ( platelet count &lt; 100,000/µl ) Any history hemorrhagic stroke intracranial hemorrhage , transient ischemic attack ( TIA ) ischemic stroke within past 6 month A know intolerance study drug ( aspirin , clopidogrel ticagrelor ) Patients require longterm oral anticoagulant cilostazol Any surgery require general anesthesia discontinuation aspirin and/or ADP antagonist plan within 12 month procedure . A diagnosis cancer ( superficial squamous basal cell skin cancer ) past 3 year current treatment active cancer . Any clinically significant abnormality identify screen visit , physical examination , laboratory test , electrocardiogram , judgment Investigator , would preclude safe completion study . Hepatic disease biliary tract obstruction , significant hepatic enzyme elevation ( ALT AST &gt; 3 time upper limit normal ) . Life expectancy &lt; 5 year noncardiac cardiac cause Unwillingness inability comply procedure describe protocol . Patient 's pregnant breastfeeding childbearing potential .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>bioresorbable vascular scaffold</keyword>
	<keyword>coronary artery disease</keyword>
</DOC>